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Introduction
Most large long-term studies of vagus nerve stimulation (VNS) for intractable epilepsy have found less seizures with increasing treatment durations, but those studies allowed concomitant changes in antiepileptic drugs (AEDs). [1] [2] [3] [4] In one small study of 16 children with epileptic encephalopathies, no changes in AEDs occurred during the first year of VNS; the median seizure rate reduction was 17%. 5 However, during the second year of that study, AED changes were allowed, and seizures were reduced by 43%. It remains unclear if the better responses seen with longer VNS exposures might be attributable to changed AEDs rather than to sustained VNS, or due to a combination of differing mechanisms of action of VNS and new AEDs. Previously, we reported that no specific AED seems to have unique additive antiseizure effects with VNS. 6 Changes in stimulation parameters over time also may affect outcomes, 7 but the long-term effects of parameter manipulation alone, with unchanged AEDs, have not been studied.
The VNS treatment outcome registry afforded us a unique opportunity to identify and study a large number of patients who received VNS but did not change their medical therapy. We were able to locate a sizable cohort of 269 patients in the registry who stayed on exactly the same AEDs, at exactly the same doses, for their entire first year of VNS. Thus, any long-term results reasonably could be attributed to VNS. This was not a randomized prospective trial of various stimulation settings. However, in search of general trends, we divided our study population into subgroups according to stimulation parameters employed, and other patient clinical characteristics, and compared seizure rate outcomes between these subgroups.
Methods
The VNS patient outcome registry is a database created by participating prescribing physicians who voluntarily submit, to a centralized data storage site, baseline patient clinical information on the patients they treat, and then submit follow-up information at various intervals during this therapy. Baseline data collected about the patients include: age, epilepsy syndrome (localization-related, Lennox-Gastaut Syndrome [ LGS], or other generalized), age of epilepsy onset, gender, baseline seizure rates, baseline AEDs, and history of previous intracranial epilepsy surgery. Follow-up data collected 3 and 12 months after VNS implantation include: seizure frequency, VNS parameters, and AED type and dose.
We were able to identify 269 patients with 1 year of VNS treatment who did not change their AED or their AED dose. No AEDs were added or removed. We analyzed changes in seizure rates in these 269 patients after 3 and 12 months of VNS therapy, relative to historical baseline. The relationships between stimulation parameters, various patient clinical characteristics, and changes in seizures rates were studied. Nonparametric statistical analyses were employed when appropriate. Standard techniques for the surgical implantation of, and treatment of medication-resistant epilepsy with, VNS were employed. [8] [9] [10] 
Results

Patient demographics
Clinical characteristics of the patient population are shown in Table 1 . The majority had localization-related epilepsy (67%). The other third of patients had LGS or some other form of generalized epilepsy. Durations of epilepsy before VNS im- 
Changes in seizure rates over the first year of VNS therapy
Median seizure rate reduction was 45% after 3 months of VNS (P < 0.0001, Wilcoxon sign-rank test) and 58% after 12 months (P < 0.0001). This represents a significant improvement between 3 and 12 months (P < 0.0001, Wilcoxon sign-rank test). The relative frequency of patients with ≥50, ≥75, ≥90, and 100% seizure rate reductions all increased between 3 and 12 months follow-up ( Fig. 1) .
Stimulation parameters and changes in seizure rates
One explanation for declining seizure rates with longer VNS exposures might be that higher stimulation settings are achieved with greater follow-up durations. While treating physicians can adjust various stimulation parameters (output current, stimulation on-time, stimulation off-time, stimulation frequency, pulse width), the most commonly modified parameters are output current and off-time. 9 Therefore, we subdivided and analyzed patients' seizure rate responses according to output currents and on/off-time (''duty'') cycles.
Output current
Stimulation currents were classified as ''low'' (0.25-1.00 mA), ''medium'' (1.25-2.0 mA), or ''high'' (≥2.25 mA). Seizure rate changes at 12 months follow-up for these groups are shown in Table 2 . Patients with high output current exhibited less seizure rate change (median 38% reduc- tion) than those with low (64%) and medium (61%) output currents (P = 0.0197, Kruskal-Wallis test). This may indicate that high output currents are less effective than low and medium currents; that the high output currents increase the seizure rate in some cases; or that treating physicians increased output currents in patients who did not respond initially to lower settings.
Duty cycle
Seizure rate reductions at 12 months follow-up are shown for patients with off-times of ≤1.1, 1.8, 3.0, and ≥5.0 min in Table 3 . ''Standard'' (std) cycling was defined as off-times ≥3.0 min; ''rapid'' (rpd) cycling was defined as off-times ≤1.8 min. There was no significant difference in seizure rate reduction between standard cycling (median 62%) and rapid cycling (50%) (P = 0.551, Wilcoxon rank-sum test). We further studied the effects of the sequence of cycling settings at 3 and 12 months on changes in seizure rates (Table 4) . Patients were classified as std-std (std at 3 and 12 months), std-rpd (std at 3 and rpd at 12 months), or rpd-rpd (rpd at 3 and 12 months) (there were only three std-rdp patients; these three were excluded from compar- isons). The median seizure rates declined between 3 and 12 months follow-up in all three groups; this decline was significant for the std-std (45-63%, P = 0.0004, Wilcoxon sign-rank test) and rpdrpd (67-80%, P = 0.008, Wilcoxon sign-rank test) groups, and approached significance for the stdrpd group (40-50%, P = 0.092, Wilcoxon sign-rank test). The seizure rate reduction after 12 months of VNS therapy was notable in the rpd-rpd subgroup (median 80%), but the number of patients in this group was small (n = 21). Upon direct comparison, there were no significant differences between the degrees of seizure rate declines from 3 to 12 months when comparing the std-std and rpd-rpd (P = 0.1198, Wilcoxon rank-sum test) and std-std and std-rpd (P = 0.3938, Wilcoxon rank-sum test) groups. There were 13 patients who were on exactly the same VNS settings, in addition to being on the exact same AEDs and dosages, at 3 and 12 months follow-up. Their median seizure rate reduction was 36% after 3 months, and declined further to 
Patient clinical characteristics and changes in seizure rate
Univariate linear regression models did not reveal independent significant effects of gender, age of epilepsy onset, baseline seizure rate, number of baseline AEDs, or history of lobectomy epilepsy surgery on seizure rate outcomes at 12 months follow-up (Table 5 ). Significant effects of epilepsy syndrome (P = 0.003), age (P = 0.016), and duration of epilepsy (P = 0.033) were observed, and previous corpus callosotomy approached significance (P = 0.075). Median seizure rate reductions at 12 months were 37% for LGS patients (n = 22), 55% for patients with other generalized epilepsies (n = 63), and 65% for patients with localization-related epilepsy (n = 184). The patients' median age was 32 years. The median seizure rate reduction at 12 months follow-up for patients <32 years old was 50%; the median seizure rate reduction at 12 months follow-up for patients ≥32 years was 64%. The median duration of epilepsy was 22 years. The median seizure rate reduction at 12 months follow-up for patients with epilepsy <22 years was 55%; the median seizure rate reduction at 12 months for patients with epilepsy for ≥22 years was 64%.
Discussion
Registry methodology
The VNS treatment registry offers some desirable attributes as a research tool. 6 First and foremost is the large number of patients enrolled by various treating physicians. We enjoyed the unique circumstance of being able to identify and study a very sizable cohort of 269 patients on VNS and on exactly the same AEDs at the same dosages for 1 year. No previous study has described such a large patient population in which the only therapeutic maneuver was the addition of VNS.
However, registries may be subject to patient selection bias. All physicians prescribing VNS do not participate, and participating physicians may not register every patient. Thus, registry patients may not be representative of all patients treated with VNS.
We attempted to minimize the effects of patient selection bias by focusing on comparisons between subgroups within the registry, or between seizure rate changes at different treatment intervals within our study population. We avoided drawing general conclusions about the expected degree of VNS treatment efficacy in all treated patients, since the registry cases may or may not be representative of all treated patients. Which patients are entered into the registry may reflect certain physician behavior trends, and this may bias the absolute degree of seizure rate changes we observed. However, such trends should be similarly operative at 3 and 12 months of VNS treatment, and most likely would not explain the relative progressive change in seizure rates over time we observed in our constant cohort of 269 patients.
Seizure rate changes over time
Studies have shown declining seizure rates with increasing VNS exposure duration. 1 In an open-label extension study of 454 patients exiting precommercial-approval prospective clinical trials, Morris et al. 2 reported median seizure rate reductions of 20% after 3 months of treatment, 35% after 1 year, and 44% after 3 years. The degree of improvement in our study at 1 year was greater than this. This difference may reflect the post-commercial-approval clinical experience nature of our data.
Previously, there have been no large long-term studies in which AEDs were held totally constant and only VNS was added. In our study, not only were no new AEDs added, but also there were no changes in doses of baseline AEDs. Therefore, the progressive seizure rate decline we observed must be attributed to VNS alone. It is not likely that this degree of improvement occurred spontaneously in these refractory patients.
Stimulation parameters
We were unable to demonstrate any particular stimulation parameter characteristics that had obvious greater efficacy than any others. The 46 patients with output currents ≥2.25 mA at 12 months follow-up did not respond as well as did the other patients. Caution is in order when assessing the general significance of these results because of the nature of our research design. Patients were not randomized to various stimulation settings; physicians chose, changed or continued various settings on a case-by-case basis based on their medical judgment and VNS efficacy and tolerability for each individual patient. These circumstances may have obscured subtle differences between effectiveness of various stimulation parameters. For example, we do not know whether patients who initially responded well to low stimulation currents, and remained at those settings, would have improved even further if their currents had been increased subsequently. However, in agreement with our findings, recently published preliminary results of a randomized trial of different VNS settings have failed to suggest any superior stimulation treatment approach. 9 
Stimulation parameter changes over time
One hypothesis to explain greater average seizure rate reductions with longer VNS therapy might be that with longer exposures, more patients achieve higher stimulation settings (higher currents or duty cycles changed to rapid cycling), and these are more effective. Our results do not support this hypothesis. As noted above, we found increased current and increased duty cycles were not associated with greater seizure rate reductions. Furthermore, there was no difference between patients who stayed on standard cycling and patients who switched from standard cycling to rapid cycling. This suggests that accumulating effects of stimulation per se, and not changes in stimulation settings, lead to late improvement.
Similar to us, in a long-term study of 154 localization-related epilepsy patients on VNS, DeGiorgio et al. 7 found no association between particular stimulation parameter settings and seizure rate reductions at 1-year follow-up. They did, however, report a significant reduction in seizure rates between 3 and 12 months follow-up in patients who had their stimulation duty cycles changed from ''standard'' cycling to off-times ≤1.1 min. In that study the patients who were changed to rapid cycling by 12 months follow-up were patients who had experienced only minimal seizure rate reductions at 3 months. Thus, their ''improvement'' between 3 and 12 months only changed their response from ''less than average'' to ''average''. This is another example of the difficulties encountered when attempting to study treatment efficacy based on clinical experience rather than on outcomes of prospective randomized clinical trials.
Predicting responsiveness to VNS
Clinical patient features that reliably predict responsiveness to VNS therapy have proved elusive. A summary of the results of previous studies on this topic is presented in Table 6 . This table illustrates a great lack of consistency between reports; many features said to be predictive of VNS responsiveness in one paper were not confirmed as such in other papers. These reports vary greatly in study designs, study durations, and patient populations. Some papers frankly contradict each other. For example, we found greater duration of epilepsy was associated with better responsiveness to VNS. This directly contradicts Refroe and Wheless, 18 who using different methodology, found patients with seizures for less than 5 years before VNS implantation did better than patients implanted later in the course of their illness. We found greater seizure rate reductions in patients older than 32 years compared with younger patients, whereas Wernicke et al. 11 found greater seizure rate reductions in patients younger than 34 years. Previous separate reports indicate seizure rates improve similarly in older patients 19 and children. 5, 12, [15] [16] [17] Comparing separate independent studies (Refs. 5, 12, [15] [16] [17] versus Ref. 19 ) is not equivalent to direct comparisons of different aged subgroups within a single study population, as we carried out.
Three earlier reports suggested that patients who previously underwent corpus callosotomy did well with VNS; 12, 16, 17 we saw a similar trend in our study. In summary, however, it appears that, for most patients, we are as of yet unable to predict whether seizures will respond to VNS therapy based on their clinical characteristics.
Conclusions
Our results suggest the following:
1. Seizure rates decline with increasing duration of VNS therapy. 2. This seizure rate decline can occur without changes in AEDs. 3. This decline is not due to sequential changes in stimulation parameters. 4. Similar degrees of long-term seizure rate reduction are seen on various VNS stimulation settings. 5. Clinical predictors of VNS responsiveness remain elusive.
